The hemp-derived CBD company’s latest results show why lower revenue and an improving quarterly loss can coexist—and why neither resolves the policy outlook.
Texas HB 507 would restrict cannabinoid screening for many public workers, with explicit exceptions. The November 9 filing is a proposal, not enacted law.
MoreBetter plans Mississippi patient-reported cannabis research for early 2027. Here’s what the observational program aims to measure.
Missouri’s new research framework covers more than clinical studies, but a facility license alone will not authorize a project to begin.
Sixteen governors urge Congress to act on cannabis banking. GAO findings explain why accounts, payments and lending remain separate challenges.
New Senate appropriations language asks for more evidence on medical cannabis and opioid use among veterans, while important research questions remain unresolved.
A new British cannabis analysis estimates daily or near-daily use and explains why frequency, age and survey definitions matter.
DEA’s new production quota proposal includes Schedule I cannabis figures while a separate Schedule III cannabis notice remains to come.
Washington’s medical cannabis proposal addresses labeling, testing and product classifications. A November 10 hearing precedes any final rule.
A small UCLA trial finds cannabis responses depend on sex and consumption frequency, challenging a simple assumption about sensitivity.